Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma

Cancer Gene Ther. 2016 Nov;23(11):371-372. doi: 10.1038/cgt.2016.45. Epub 2016 Oct 14.

Abstract

Neuroblastoma (NB) is known as a pediatric neoplasm that is associated with variable histopathological features. The use of biomarkers contributes to the monitoring and treatment of various malignancies such as NB. The identification of novel biomarkers such as (epi)genetic biomarkers and microRNAs (miRNAs) in NB has led to better treatments of NB. Among them, miRNAs have emerged as powerful tools in diagnosis, prognosis and therapeutic biomarkers for patients with NB. Circulating biomarkers such as circulating miRNAs present in body fluids (for example, plasma, serum and urine) provided an interesting field of study in NB treatment. The miRNAs have central roles in different pathogenic events in various malignancies such as NB. Hence, these molecules can be a suitable candidate for monitoring and treating NB patients. Here, we summarize some miRNAs as potential prognosis, diagnosis and therapeutic biomarkers in NB.

MeSH terms

  • Biomarkers, Tumor / blood*
  • Circulating MicroRNA / blood*
  • Early Detection of Cancer
  • Humans
  • Neuroblastoma / blood*
  • Neuroblastoma / diagnosis

Substances

  • Biomarkers, Tumor
  • Circulating MicroRNA